ArriVent BioPharma, Inc. Common Stock
General ticker "AVBP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $741.9M (TTM average)
ArriVent BioPharma, Inc. Common Stock follows the US Stock Market performance with the rate: 8.4%.
Estimated limits based on current volatility of 3.8%: low 24.04$, high 25.91$
Factors to consider:
- Total employees count: 40 as of 2023
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [16.86$, 42.44$]
- 2025-12-31 to 2026-12-31 estimated range: [11.49$, 30.44$]
Short-term AVBP quotes
Long-term AVBP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $36.91MM | $74.59MM | $94.31MM |
| Operating Income | $-36.91MM | $-74.59MM | $-94.31MM |
| Non-Operating Income | $0.00MM | $5.26MM | $13.82MM |
| R&D Expense | $30.43MM | $64.88MM | $79.00MM |
| Income(Loss) | $-36.91MM | $-69.33MM | $-80.49MM |
| Profit(Loss)* | $-36.91MM | $-69.33MM | $-80.49MM |
| Stockholders Equity | $174.46MM | $151.30MM | $257.65MM |
| Assets | $182.83MM | $163.10MM | $274.94MM |
| Operating Cash Flow | $-43.63MM | $-55.84MM | $-70.21MM |
| Investing Cash Flow | $0.00MM | $0.00MM | $-192.47MM |
| Financing Cash Flow | $169.72MM | $42.86MM | $186.58MM |
| Earnings Per Share** | $-1.10 | $-2.17 | $-2.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.